Cytosorbents (CTSO) Revenue (2011 - 2026)

Cytosorbents has reported Revenue for 16 years, with the latest figure at $8.9 million in Q1 2026.

• For the quarter ending Q1 2026, Revenue rose 1.57% year-over-year to $8.9 million; the trailing twelve-month figure through Mar 2026 stood at $37.2 million (up 5.28% YoY), and the FY2025 full-year result was $37.1 million, up 4.12% from the prior year.
• Revenue for Q1 2026 stood at $8.9 million, down from $9.2 million in the prior quarter.
• The five-year high for Revenue was $9.6 million in Q2 2025, with the low at $8.1 million in Q3 2022.
• Historically, Revenue has averaged $9.0 million across 5 years, with a median of $8.9 million in 2026.
• Annual changes were most pronounced in 2022 — Revenue fell 29.35% — and 2023, when it increased 10.89%.
• Cytosorbents' Revenue stood at $9.4 million in 2022, then declined by 7.69% to $8.7 million in 2023, then increased by 5.57% to $9.2 million in 2024, then climbed by 0.91% to $9.2 million in 2025, then retreated by 4.01% to $8.9 million in 2026.
• The last three Revenue figures came in at $8.9 million (Q1 2026), $9.2 million (Q4 2025), and $9.5 million (Q3 2025), per Business Quant data.